Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

March 13, 2018; 90 (11) Article

Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis

Jeremy Chataway, Keith Martin, Kevin Barrell, Basil Sharrack, Pelle Stolt, David C. Wraith, For the ATX-MS1467 Study Group
First published February 21, 2018, DOI: https://doi.org/10.1212/WNL.0000000000005118
Jeremy Chataway
From the Queen Square Multiple Sclerosis Centre (J.C.), Department of Neuroinflammation, UCL Institute of Neurology, University College London; Apitope Technology (Bristol) Ltd. (K.M., K.B., D.W.), Chepstow; Academic Department of Neuroscience (B.S.), NIHR Sheffield Neuroscience Biomedical Research Centre, University of Sheffield, UK; MagliaRotta (P.S.), Basel, Switzerland; and Institute of Immunology and Immunotherapy (D.C.W.), Birmingham, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith Martin
From the Queen Square Multiple Sclerosis Centre (J.C.), Department of Neuroinflammation, UCL Institute of Neurology, University College London; Apitope Technology (Bristol) Ltd. (K.M., K.B., D.W.), Chepstow; Academic Department of Neuroscience (B.S.), NIHR Sheffield Neuroscience Biomedical Research Centre, University of Sheffield, UK; MagliaRotta (P.S.), Basel, Switzerland; and Institute of Immunology and Immunotherapy (D.C.W.), Birmingham, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Barrell
From the Queen Square Multiple Sclerosis Centre (J.C.), Department of Neuroinflammation, UCL Institute of Neurology, University College London; Apitope Technology (Bristol) Ltd. (K.M., K.B., D.W.), Chepstow; Academic Department of Neuroscience (B.S.), NIHR Sheffield Neuroscience Biomedical Research Centre, University of Sheffield, UK; MagliaRotta (P.S.), Basel, Switzerland; and Institute of Immunology and Immunotherapy (D.C.W.), Birmingham, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Basil Sharrack
From the Queen Square Multiple Sclerosis Centre (J.C.), Department of Neuroinflammation, UCL Institute of Neurology, University College London; Apitope Technology (Bristol) Ltd. (K.M., K.B., D.W.), Chepstow; Academic Department of Neuroscience (B.S.), NIHR Sheffield Neuroscience Biomedical Research Centre, University of Sheffield, UK; MagliaRotta (P.S.), Basel, Switzerland; and Institute of Immunology and Immunotherapy (D.C.W.), Birmingham, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pelle Stolt
From the Queen Square Multiple Sclerosis Centre (J.C.), Department of Neuroinflammation, UCL Institute of Neurology, University College London; Apitope Technology (Bristol) Ltd. (K.M., K.B., D.W.), Chepstow; Academic Department of Neuroscience (B.S.), NIHR Sheffield Neuroscience Biomedical Research Centre, University of Sheffield, UK; MagliaRotta (P.S.), Basel, Switzerland; and Institute of Immunology and Immunotherapy (D.C.W.), Birmingham, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David C. Wraith
From the Queen Square Multiple Sclerosis Centre (J.C.), Department of Neuroinflammation, UCL Institute of Neurology, University College London; Apitope Technology (Bristol) Ltd. (K.M., K.B., D.W.), Chepstow; Academic Department of Neuroscience (B.S.), NIHR Sheffield Neuroscience Biomedical Research Centre, University of Sheffield, UK; MagliaRotta (P.S.), Basel, Switzerland; and Institute of Immunology and Immunotherapy (D.C.W.), Birmingham, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
From the Queen Square Multiple Sclerosis Centre (J.C.), Department of Neuroinflammation, UCL Institute of Neurology, University College London; Apitope Technology (Bristol) Ltd. (K.M., K.B., D.W.), Chepstow; Academic Department of Neuroscience (B.S.), NIHR Sheffield Neuroscience Biomedical Research Centre, University of Sheffield, UK; MagliaRotta (P.S.), Basel, Switzerland; and Institute of Immunology and Immunotherapy (D.C.W.), Birmingham, UK.
Full PDF
Citation
Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis
Jeremy Chataway, Keith Martin, Kevin Barrell, Basil Sharrack, Pelle Stolt, David C. Wraith, For the ATX-MS1467 Study Group
Neurology Mar 2018, 90 (11) e955-e962; DOI: 10.1212/WNL.0000000000005118

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
307

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

Objective To assess safety, tolerability, and efficacy of the antigen-specific immunotherapy ATX-MS-1467 in participants with relapsing multiple sclerosis using different treatment protocols to induce tolerance.

Methods Two open-label trials in adult participants with relapsing multiple sclerosis were conducted. Study 1 was a multicenter, phase 1b safety evaluation comparing intradermal (i.d.) (cohort 1) with subcutaneous (cohort 2) administration in 43 participants. Both cohorts received ATX-MS-1467 dosed at 25, 50, 100, 400, and 800 μg at 14-day intervals over 8 weeks, followed by 8 weeks with 4 additional 800-μg doses at 14-day intervals and 32 weeks off study medication. Study 2 was a phase 2a, multicenter, single-arm trial enrolling 37 participants. ATX-MS-1467 was titrated from 50 μg i.d. on day 1 to 200 μg on day 15 and 800 μg on day 29 followed by biweekly administration of 800 μg for 16 weeks and 16 weeks off study medication. Efficacy was evaluated on MRI parameters and clinical variables. Safety endpoints included treatment-emergent adverse events and injection-site reactions.

Results In study 1, there was a significant decrease in new/persisting T1 gadolinium-enhanced (GdE) lesions in cohort 1 from baseline to week 16, returning to baseline values at week 48. In study 2, the number of T1 GdE lesions were significantly reduced on treatment and remained reduced at study completion. Safety results were unremarkable in both studies.

Conclusion Relatively slow ATX-MS-1467 titration and a longer full-dose i.d. treatment period is associated with reduction in GdE lesions and a sustained effect post treatment. Further trials of ATX-MS-1467 are warranted.

Classification of evidence This work provides Class IV evidence that for patients with relapsing multiple sclerosis, slow ATX-MS-1467 titration and a longer full-dose i.d. treatment period is associated with reduction in GdE lesions.

Glossary

AE=
adverse event;
ARR=
annualized relapse rate;
EDSS=
Expanded Disability Status Scale;
GdE=
gadolinium-enhanced;
i.d.=
intradermal;
ITT=
intention-to-treat;
MBP=
myelin basic protein;
mITT=
modified intention-to-treat;
MS=
multiple sclerosis;
MSFC=
Multiple Sclerosis Functional Composite;
RMS=
relapsing multiple sclerosis;
s.c.=
subcutaneous;
TEAE=
treatment-emergent adverse event

Footnotes

  • Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • ATX-MS1467 Study Group coinvestigators are listed at links.lww.com/WNL/A233.

  • Class of Evidence: NPub.org/coe

  • Received July 31, 2017.
  • Accepted in final form December 8, 2017.
  • © 2018 American Academy of Neurology
View Full Text

AAN Members

We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.

Google Safari Microsoft Edge Firefox

Click here to login

AAN Non-Member Subscribers

Click here to login

Purchase access

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here 

Purchase
Individual access to articles is available through the Add to Cart option on the article page.  Access for 1 day (from the computer you are currently using) is US$ 39.00.  Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means.  The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use.  Distributing copies (electronic or otherwise) of the article is not allowed.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Glossary
    • Methods
    • Results
    • Discussion
    • Author contributions
    • Study funding
    • Disclosure
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

  • All Clinical trials
  • Multiple sclerosis
  • Class III

Alert Me

  • Alert me when eletters are published
Neurology: 99 (1)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise